Media Coverage
- Feb 7 2012
- Jan 4 2012
- Sep 29 2011
- Sep 2 2011
- Sep 1 2011
- Aug 30 2011
Press Releases
- Jan 4 2012
- Sep 29 2011
- Sep 9 2011
- Aug 18 2011
News and Media
More On Colucid
Our pipeline of novel CNS compounds includes lasmiditan, a first in class Neurally Acting Anti-Migraine Agent (NAAMA), and COL-204 for wake promotion.
Patent information for COL-204 and Conjugated Stigmine Platform can be found on our patents page.
About Migraines
Approximately 30 million Americans have migraines (13% of adult population)
- 18% of women and 6% of men experience migraines
- Most common in working population from 25 to 55 years old
- Direct medical expenditures exceed $11 billion per year in U.S.
About Colucid
CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures.